Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sean Tu

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
JAMA Internal Medicine|May 11, 2026
Delisting of Pharmaceutical Patents Challenged by the Federal Trade CommissionJennifer Leon, S Sean Tu, Aaron S Kesselheim, et al.
JAMA|August 1, 2023
Changes in the Number of Continuation Patents on Drugs Approved by the FDAS Sean Tu, Aaron S Kesselheim, Kathrine Wetherbee, et al.
Journal of General Internal Medicine|July 14, 2025
Revenue, Patents, and New Generic Competition for Prescription Drugs in the USAS Sean Tu, Aaron S Kesselheim, Joseph S Ross, et al.
Journal of General Internal Medicine|July 16, 2025
Prescription Drug Method-of-Use Patent Protection, 1991-2018Doni Bloomfield, Theodore W Teng, Aaron S Kesselheim, et al.
JAMA|November 13, 2023
Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated ProductsS Sean Tu, Caroline Leadmon, C Joseph Ross Daval, et al.
Nature Biotechnology|July 14, 2023
The prevalence of drug patent term extensions in the United States, 2000-2018Victor L Van de Wiele, Aaron S Kesselheim, Sarosh Nagar, et al.
Nature Biotechnology|July 17, 2024
The cost of drug patent expiration date errorsS Sean Tu, Dinis Cheian, Sarah Gabriele, et al.
JAMA|November 21, 2024
Characteristics of Academic Inventors on Government-Linked US Drug PatentsMatthew J Martin, Sarah M E Gabriele, Aaron S Kesselheim, et al.
Nature Biotechnology|August 12, 2025
Jefferson et al. replyOsmat Jefferson, W Nicholson Price, S Sean Tu, et al.
JAMA|May 9, 2023
Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act DesignationS Sean Tu, Sarosh Nagar, Aaron S Kesselheim, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
JAMA Internal Medicine|May 11, 2026
Delisting of Pharmaceutical Patents Challenged by the Federal Trade CommissionJennifer Leon, S Sean Tu, Aaron S Kesselheim, et al.
JAMA|August 1, 2023
Changes in the Number of Continuation Patents on Drugs Approved by the FDAS Sean Tu, Aaron S Kesselheim, Kathrine Wetherbee, et al.
Journal of General Internal Medicine|July 14, 2025
Revenue, Patents, and New Generic Competition for Prescription Drugs in the USAS Sean Tu, Aaron S Kesselheim, Joseph S Ross, et al.
Journal of General Internal Medicine|July 16, 2025
Prescription Drug Method-of-Use Patent Protection, 1991-2018Doni Bloomfield, Theodore W Teng, Aaron S Kesselheim, et al.
JAMA|November 13, 2023
Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated ProductsS Sean Tu, Caroline Leadmon, C Joseph Ross Daval, et al.
Nature Biotechnology|July 14, 2023
The prevalence of drug patent term extensions in the United States, 2000-2018Victor L Van de Wiele, Aaron S Kesselheim, Sarosh Nagar, et al.
Nature Biotechnology|July 17, 2024
The cost of drug patent expiration date errorsS Sean Tu, Dinis Cheian, Sarah Gabriele, et al.
JAMA|November 21, 2024
Characteristics of Academic Inventors on Government-Linked US Drug PatentsMatthew J Martin, Sarah M E Gabriele, Aaron S Kesselheim, et al.
Nature Biotechnology|August 12, 2025
Jefferson et al. replyOsmat Jefferson, W Nicholson Price, S Sean Tu, et al.
JAMA|May 9, 2023
Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act DesignationS Sean Tu, Sarosh Nagar, Aaron S Kesselheim, et al.
Pageof 6